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ardiovascular Imaging Research
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ardiovascular (CV) imaging plays a critical role in therapeutic decision making and is performed in
ore than 10 million patients each year; a large share of the nearly 40 million patients living with CV
isease. CV imaging may serve as a valuable component of a patient’s evaluation, provided that its
nhanced diagnostic ﬁndings invoke appropriate and targeted therapies that improve symptom
urden and long-term outcomes and are not offset by the upfront procedural and induced costs of care.
s well, the overall clinical beneﬁt that imaging imparts to the patient must signiﬁcantly outweigh any
ntoward risk, including radiation or procedural complications. Explosive growth in imaging has
esulted in a rapid escalation of costs for testing encumbering an estimated $80 billion dollars annually
nd represents a sizeable portion of cardiologists’ income. Concern remains that continued expansion
f CV imaging services may further add to the complexity of health care services and magnify the
ocietal burden of health care. The ﬁeld of CV imaging is beset by high procedural use, high growth
ates, and often, a lack of demonstrable quality. The end result of our current health care system and
eimbursement models is an over emphasis on volume and throughput, extensive efforts necessary for
ustiﬁcation of procedural use, and a broad referral population exceeding guideline-accepted best
ractices. An inextricable link between imaging markers and outcomes forms a critical nexus that can
e used to establish the value of a test, and is now the standard upon which technology will be
valuated by private payers and governmental agencies alike. This new benchmark necessitates
igh-quality research to compare the effectiveness of CV imaging modalities to elicit improvements in
ealth outcomes; representing a dramatic paradigm shift for the ﬁeld of CV imaging research. In this
eview, we will discuss current health policy of CV imaging as well as the future of CV imaging-based
omparative effectiveness research.C
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of significant morbidity and mortality
in the U.S. and is rapidly expanding
in developed and developing countries
orldwide (1). In the U.S., CV imaging plays a
ritical role in therapeutic decision making and
s performed in more than 10 million patients
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317ach year; a large share of the 40
illion patients living with CV disease
2,3). CV imaging may serve as a valu-
ble component of a patient’s evalua-
ion provided that its enhanced diag-
ostic findings invoke appropriate and
argeted therapies that improve symp-
om burden and long-term outcomes;
et are not offset by high upfront pro-
edural and induced costs of care. As
ell, the overall clinical benefit that is
mparted to the patient must signifi-
antly outweigh any untoward risks as-
ociated with imaging, including radi-
tion or procedural complications.
This inextricable link between imag-
ng markers and outcomes forms a
ritical nexus which can be used to
stablish the value of a test, and is now
he standard upon which technology
ill be evaluated by private payers and
overnmental agencies alike (4). This
ew benchmark necessitates high-
uality research to compare the effec-
iveness of CV imaging modalities to
licit improvements in health outcomes
nd represents a dramatic paradigm
hift for the field of CV imaging re-
earch that will be discussed in this
eview. Further discussion will ensue
n the development of evaluative stan-
ards to assess quality imaging and the
f a new era in pivotal imaging trials
omparing health outcomes. Our initial
iscussion, however, will focus on the
urrent state of CV imaging health
olicy.
urrent Health Policy of CV Imaging
ver the past decade, imaging has be-
ome central to discussions on excessive
rowth and high-cost health care (5,6).
xplosive growth in imaging (twice
hat of other physician services) has
esulted in a rapid escalation of costs for
esting, encumbering an estimated $80
illion dollars annually and represent-
ng a sizeable portion of cardiologists’
ncome (7). Between 2000 and 2007,
here was a 70% increase in the rate of
rowth for imaging services (8). For (xample, nationwide utilization for
yocardial perfusion imaging was 8.54
illion studies, with Medicare allow-
ble charges of $1.1 billion dollars in
007 (9–12). For echocardiography,
edicare allowable charges increased
50% from 2000 to 2005 (13). Imag-
ng growth has yet to be correlated with
revention or postponement of major
dverse CV events (11,14).
As illustrated in Figure 1, growth in
maging reached a zenith in 2004 to
005, with recent declines noted. Rea-
ons for recent declines in imaging
tilization are multifactorial, including
ecent government regulations and in-
reasing physician awareness of appro-
riate use criteria. For example, the
eficit reduction act (DRA) was signed
nto law in 2005 and affected many
omestic entitlement programs, in-
luding Medicare. The DRA impacted
maging utilization in 2006 to 2007
ith resultant attenuation of growth
nd declining Medicare allowable
harges for imaging services. Despite
ecent reductions, concerns remain that
ny expansion of CV imaging services
nd its associated economic conse-
uences may further add to the com-
lexity of health care services and mag-
ify the societal burden of health care.
recent Government Accounting Of-
ce report on imaging growth also
ontends there is frequent inappropri-
te and unnecessary testing (15).
In many ways, the field of CV imaging is
mblematic of challenges facing all of med-
cine. The field is beset by high procedural
se, high growth rates, and often, a lack of
emonstrable quality. The end result of our
urrent health care system and reimburse-
ent models is an overemphasis on volume
nd throughput, extensive efforts necessary
or justification of procedural use, and a
apacious referral population exceeding
uideline-accepted best practices. In 1 re-
ent analysis, nearly one quarter of referrals
o stress myocardial perfusion single-
hoton emission computed tomography
SPECT) and echocardiography were of
ncertain appropriateness or inappropriate
16). The expansion of services has placed fV imaging within the crosshairs of payers
nd governmental agencies that have been
harged with curtailing unnecessary and
xcessive health care spending. Recently,
he Centers for Medicare & Medicaid Ser-
ices (CMS) physician fee schedule for
chocardiography and nuclear imaging was
eleased and included40% cuts for 2010
17). Utilization management efforts in-
luding mandatory prior authorization
y radiology benefits managers are now
tandard practice. The realization that
ontinued imaging growth is econom-
cally unsustainable has precipitated de-
ands for more robust evidence to
upport imaging use.
Although minimizing unnecessary im-
ging is a laudable goal, abolition of all
rowth is probably not. Given the aging
f our population combined with an ex-
anding prevalence of obesity and diabe-
es (18–20), a certain amount of growth
n CV imaging is expected. Quantifying
he extent to which worsening popula-
ion health contributes to increasing im-
ging utilization will aid in the discrimi-
ation of which testing is unnecessary
ersus which may be justified. Indeed,
here is some evidence to suggest that
maging intensity is related to disease
urden (21). Evidence also suggests that
vertesting does occur; particularly annu-
lly or in low-risk patients (22,23). At
resent, the lack of high-quality evidence
as created an environment of uncer-
ainty on the part of referring physicians
nd guideline writers, leading to wide
ariability and imprecision in clinical de-
ision making surrounding the use of CV
maging. This lack of evidence demon-
trating in whom and when a patient
hould be referred to or re-evaluated by
V imaging is conducive to developing
atterns of inefficiency that are driven by
actors external to evidence-based medi-
ine. Definitive evidence establishing that
given CV imaging modality results in
mproved health status or clinical out-
omes can guide referring physicians to
ake optimal test choices.
At both the societal and patient
evel, one key process by which to guide
uture imaging use is the development
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318f pathways of accountability for imag-
ng practices. The result of this would
e a reduction in marked variation in
maging utilization and a greater em-
hasis on quality. In this regard, high
uality evidence on the comparative
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Figure 1. Growth in Imaging as Compared With
(A) Cumulative changes in cardiac imaging are included
cardiac imaging (dashed lines), data for stress myocardi
(Angio), and stress echocardiography (Stress Echo) were
black line at year 2005 signiﬁes the effective date of the
imaging utilization have been reported. *Cardiac imagin
and includes Medicare Part B utilization data only. Adap
(B) An example of growth and attenuation in imaging c
care allowable charges for Current Procedural Terminolo
nation (Exam) of the Heart from 2000 to 2007 (13).ffectiveness of alternative CV imaging ptrategies is necessary to guide optimal
linical decision making. Interim steps
ut forth by the American College of
ardiology (ACC) and American Col-
ege of Radiology (ACR) now devise
rocedural and multimodality appro-
ears
DRA
003 2004 2005 2006
*
PI
ngio
Stress Echo
ears
2005 2006 2007
Echo Exam of the
Heart (CPT: 93307)
er Physician Services From 2000 to 2006
this ﬁgure as well as for overall imaging utilization. For
rfusion imaging (MPI), invasive coronary angiography
piled using Medicare Part B data only. The dotted
cit Reduction Act (DRA) where notable declines in
ilization was derived from the Levin et al. article (9)
ith permission from Iglehart (8) and Levin et al. (9).
es following the DRA is reported by examining Medi-
CPT) code: 93307 or Echocardiographic (Echo) Exami-riateness criteria (24–27). gutcomes Research in CV Imaging
or the practicing clinician, it is essential
o understand what defines outcomes
esearch and why it holds a pivotal role in
valuating imaging modalities. The
gency for Health Related Quality de-
nes outcomes research as an examina-
ion of the end results of a given health
are strategy (28). This term end result for
V imaging has historically meant diag-
ostic or prognostic accuracy. However,
end result” could also mean alterations
n patient’s symptoms, physical function-
ng, or quality of life. A critical element of
utcomes research is the focus on patient
enteredness to provide accountability for
he investment in CV imaging (29). For
V imaging, less frequently studied but
lso important is the role of patient pref-
rences or satisfaction with the ongoing
esting received. The use of cost as an
nd point must be couched within the
ontext of quality or effectiveness, and
or that reason it is generally a second-
ry outcome.
pplying Comparative Effectiveness
esearch to CV Imaging
utcomes research broadly refers to the
elationship between processes of care
e.g., CV imaging) to patient-centered
utcomes. More specific types of out-
omes research deal with comparing the
ffectiveness of alternative patient-
entered strategies (i.e., comparative ef-
ectiveness research [CER]) in order to
mprove practice and shape health policy
29). The goal of CER is to compare
ncremental changes in health outcomes
or a given strategy, procedure, or therapy
30). The Federal Coordinating Council
or CER defined patient-centered CER
s “. . . the conduct and synthesis of sys-
ematic research comparing different in-
erventions and strategies to prevent, di-
gnose, treat and monitor health
onditions . . . for diverse patient popula-
ions” (31).
For CV imaging, this would entail a
omparison between 2 or more strate-Y
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319ging strategies, with the primary end
oint being an assessment of net im-
rovements in health outcomes. In a
ecent analysis of the diagnostic imag-
ng literature, the CMS stated that
ost studies have focused on test char-
cteristics and have not considered
ealth outcomes (32,33). The combi-
ation of imaging-guided alterations in
atient management with established
mprovements in outcomes forms the
onnection whereby CV imaging im-
roves patient outcomes (34).
There are, however, several principles
f CER that will require changes to
usual practice” in CV imaging research
35). First, the concept that CER studies
ddress broad clinical questions is funda-
ental to this type of research. For CV
maging, this would entail evaluation of
ts additive role in patient management as
ompared with strategies that employ no
esting (i.e., is any imaging warranted?).
Adoption of a CER approach also
equires other changes in CV imaging
esearch including: populations stud-
ed, choice of end points, validation
ethodologies, and dissemination of
tudy findings (Table 1) (35). Within
V imaging research, it is common for
ample sizes to be small and limited to
few academic centers. Additionally,
he choice of end points tends to be a
ixture of fatal and morbid complica-
ions including subjective outcomes,
uch as unstable angina or revascular-
zation (36–38). It is imperative for
Table 1. Comparative Effectiveness Research—N
New Standards
CER entails broad clinical areas impacting large seg
population
End point selection: transparency of end points in
clinical outcomes
Validation methodologies: an important part of com
research is the validation of study ﬁndings in eth
populations of women and men across varied cl
Dissemination of study ﬁndings to patients, health
policymakers
CER  comparative effectiveness research; CV  cardiovascesearchers to take time to develop Ceaningful patient series with rigor-
usly collected, quantitative end points,
nd that cohorts are broadly represen-
ative of patient subgroups and practice
ettings to ensure generalizability of
esults. All events should be clearly
escribed in unambiguous terms with
egards to what is influencing prognos-
ic modeling. In some cases, this may
equire independent adjudication of
nd points, as is routinely performed in
linical trials. Transparency of the rela-
ionship between CV imaging abnor-
alities to prognosis is fundamental to
he development of trials or registries of
maging strategies for improving health
utcomes (39).
There is, further, a lack of standard-
zation for validation methods in CV
maging research; in particular as it
elates to prognostic findings. Valida-
ion in larger or diverse patient groups
s needed to extend the generalizability
f results to broader populations. Fi-
ally, there is a mandate for the results
f CER to be adequately communi-
ated to patients, health care providers,
nd policymakers (35). This latter
oint is fundamental to create optimal
eferral pathways to and from CV im-
ging. Optimally, educational plat-
orms for each stakeholder should be
inked to track documentation of a
ositive CER benefit on patient and
linician decision making.
Of concern is that cost containment
s a predominant driver for CER. For
Standards and Their Impact on CV Imaging Resea
ts of the Research assessing comparative
also testing versus no testing
alterations in outcomes
ion to important The admixture of events comm
refocusing toward larger reg
patient outcomes
ative effectiveness
lly-diverse
l presentations
There is a lack of methods for v
providers, and The development of standards
stakeholders is critical to imp
guided careV imaging, CER will serve to narrow testing options to modalities with de-
onstrable quality or value. However,
eliance solely on CER to guide health
are coverage decisions will render
any indications unsupported by high-
uality evidence. Moreover, there are
linical areas where large trials or reg-
stries may never be performed due to
he limited prevalence of affected pa-
ients. Accordingly, we anticipate cur-
ent approaches for defining appropri-
te CV imaging will remain necessary
or many patient indications (24–26).
evels of Quality Evidence
he development of outcomes evi-
ence plays a critical role in devising
trategies for achieving quality of care
ith CV imaging. Several decades
go, Fryback and Thornbury (40,41)
evised hierarchical levels of diagnos-
ic test evidence ranging from techni-
al quality and diagnostic/prognostic
ccuracy to establishing a test’s im-
act on clinical decision making (Ta-
le 2). What these authors further
dd were 2 higher levels of evidence
ncluding patient and societal out-
omes. For patient outcomes, achiev-
ng this level required that an imaging
odality: 1) lengthen or save lives; or
) improve health status or quality of
ife. For this assessment of net im-
rovement in health outcomes, com-
arisons include: a testing versus no
Impact
dalities for improvements in health outcomes but
ls to assess the impact of any testing on
applied in CV imaging research will require a
s sufﬁciently powered to assess meaningful
ation that require development in CV imaging
isseminating study ﬁndings to important
referral patterns and the quality of imaging-ew rch
men mo
tria
relat only
istrie
par
nica
inica
alid
care for d
roveesting strategy, or 2 or more test strat-
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320gies. Moreover, a higher level also
ncluded societal outcomes or incre-
ental cost effectiveness analysis.
Although much work has been
ompleted to understand the diagnos-
ic and prognostic accuracy of CV
maging, the development of evidence
ssessing patient or societal outcomes
s generally not available (42). The
ntroduction of these latter 2 levels, to
engthen or save lives and to improve
ealth status or quality of life, was
isionary by Fryback and Thornbury
40,41) and has yet to become a
tandard for CV imaging research
nd technology development.
A suggested revision to the CV imaging
vidence pyramid is detailed in Figure 2.
ne may envision that technical im-
rovements or association/correlation
tudies would provide qualifying evidence
or an imaging modality as a potential
ompetitor with existing technology
nd provide a necessary precondition
or CER research. Building on this, we
ropose the effectiveness pyramid to
nitiate with evidence on diagnostic se-
ectivity including diagnostic accuracy
ut also an analysis of CV imaging
arkers and their relationship with CV
isease. For all levels within this pyra-
id, comparative analyses with other
odalities or categories of imaging
arkers (i.e., ventricular function vs.
erfusion abnormalities) are required.
Moving upward in this pyramid is the
ssociation between imaging risk markers
Table 2. Fryback and Thornbury Levels of
Diagnostic Test Evidence
1) Technical quality: imaging resolution,
reliability, repeatability, and validity
2) Diagnostic accuracy: sensitivity, speciﬁcity,
predictive accuracy
3) Diagnostic impact: impact of a diagnostic test on
MD decision making or the ability of a diagnostic
test to affect the diagnostic workup
4) Therapeutic impact: impact of a diagnostic test on
patient management/affect treatment choices
5) Patient outcomes: ability of a diagnostic test
to increase the survival or quality of life
6) Societal outcomes: cost effectiveness analysis
Data from Thornbury et al. (40) and Fryback et al. (41).nd baseline symptom status (e.g., fre- iuency and stability) as well as down-
tream symptom changes following ther-
peutic management alterations. The
rognostic utility level requires that a given
maging risk marker be incrementally
redictive of CV events. It is critical for
his level of evidence to provide informa-
ion on reclassification of risk when com-
ared to: 1) clinical risk estimates; and
) other competitive imaging or nonim-
ging markers (43).
The final level of evidence is optimized
est effectiveness strategy. When com-
ared with prior levels, this level in-
ludes CER utilizing randomized con-
rolled trials or registries comparing 2
r more test-guided strategies. For ex-
mple, it could include comparisons of
V imaging modalities versus no im-
ging or the impact of 2 different tests
n outcomes. Or the effectiveness of an
stablished technique, such as nuclear
maging, may be compared against new
echnology, such as computed tomog-
aphy. Importantly, the strategy would
nfold beyond the initial episode of
are examining the influence of test-
herapeutic–linked decision making to
ear-term improvements in symptoms
nd changes in long-term outcomes.
his level of evidence would incorpo-
ate patient preferences and satisfaction
nd consider, not only clinical, but also
conomic outcomes; such that quality
s well as value could be achieved.
ractical Application of CER in
maging—What Is Needed and HowDo
e Get There?
ithin the field of CER, there is a call
or randomized trials and registries to be
ore relevant to “real world” practice and
o include enhanced representation of the
thnically and geographically diverse
ale and female patient candidate pool
44,45). There are indications that CMS
eimbursement may be withheld if study
opulations do not match the Medicare
r at-risk populations (46). Provisional
ayment may be allowed pending the
evelopment of effectiveness evidencen Medicare patients. Moreover, prin- piples of CER deemed by a recent
merican Heart Association (AHA)
tatement include studies that encom-
ass broad clinical questions with
eaning to large segments of the pop-
lation (35). Examples of CV imaging
pplication impacting large segments of
he population include: 1) the evalua-
ion of suspected CAD; 2) new onset of
eart failure; and 3) repeat testing in
atients with established CAD (47).
he Institute of Medicine reported na-
ional priorities to include comparisons
f: 1) CV imaging screening strategies
e.g., coronary artery calcium versus
arotid intima-media thickness); and 2)
oronary computed tomographic an-
iography versus invasive coronary an-
iography (48). Should research be pur-
ued in the above indications, data could
e available to guide the use of CV
maging impacting health care for mil-
ions of patients. A recent commentary
tated that the extreme variability in pro-
edural use as well as its rapid growth
ay be attenuated should there be more
recise, high-quality evidence to guide
linical decision making (49). This
trongly suggests that the investment in
V imaging CER would be offset by
esulting enhancements in efficiency,
liminating variation, and improved
ealth care quality.
Funding for large clinical trials or reg-
stries in CV imaging requires a rework-
ng of the current investment levels on
he part of public and private agencies,
ompanies, and foundations. Today,
linical trials in CV imaging are, gener-
lly, smaller trials (e.g., 300 to 800 pa-
ients) or substudies within larger clinical
rials (39). These smaller trials have in-
ufficient resources in order to answer
arger CER questions on improvements
n health outcomes.
losing the Chasm of Pre- to
ost-Approval Requirements for CER
ne solution to the current lack of evi-
ence is to require greater research prior
o Food and Drug Administration ap-
roval; resulting in a wider knowledge
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321egarding the relationship between CV
maging and outcomes when a new tech-
ology is introduced. The standards for
pproval, especially for imaging equip-
ent, are insufficient for CER. Improv-
ng the quality of pre-approval evidence
ould result in new devices, radiopharma-
euticals, or drugs entering clinical practice
ith more well-established outcomes evi-
ence. With a larger body of outcomes
vidence upon approval, this new technol-
gy could correctly guide current practice
owards improved quality health care.
The above strategy remains imperfect as
t would protract the approval process de-
aying the introduction of new technology;
endering U.S. “cutting edge” develop-
ents behind that of other countries. Thus,
nresolved in our demand for CER is the
ension between production of rapid tech-
ological advancements in CV imaging
nd the need for health outcomes data.
ole of Pharmaceutical/Equipment
anufacturers and Payers in
upporting High-Quality, Unbiased CV
maging Research
nother option for the development of
Optimized Test Effectiveness
Strategy
Prognostic Utility
Symptom Benefit
Diagnostic Selectivity
IV. Optim
 Co
  
 Inc
  
III. Prog
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Figure 2. Proposed New Hierarchy of Evidence f
CAD  coronary artery disease.ER trials and registries is funding through pharmaceutical/equipment
anufacturers or payers. Companies pro-
iding equipment or drugs for CV imag-
ng and third-party payers have yet to
ake this level of investment in clinical
esearch. Although unusual, a powerful
xample of success using this funding
oute is the Advanced Cardiac Imaging
onsortium registry supported by Mich-
gan Blue Cross (50). One can only hope
hat revisions to current funding will
nsue on the part of such companies;
iven recent National Coverage Deter-
ination (NCD) from CMS indicating
hat broader evidence on improvements
n clinical outcomes with imaging is re-
uired to form the basis for coverage
ecisions (32,33).
Realistically, CER may require re-
ources exceeding clinical research bud-
ets for many small companies. One
olution is the development of multicom-
any collaborative efforts allowing for the
evelopment of larger outcome registries
r trials to address this new, clear regu-
atory requirement. As well, nonprofit
rganizations representing the interests
f a broader industry may play an essen-
 Test Effectiveness Strategy
ative Effectiveness of 2 or More Imaging-Driven 
tegies of Care Within a Randomized Clinical Trial
ntal Cost Effectiveness of 2 or More Imaging-Driven 
tegies Within a Randomized Clinical Trial
ic Utility
y of A Given Imaging Risk Marker in Detecting Major 
rse Cardiovascular Events (i.e., Independent 
iction Exceeding Pre-Imaging, Clinical Data) 
ative Outcomes for Differing Imaging Risk Markers or 
alities; Evaluating Near- and Long-Term Clinical 
ome Benefits
Benefit
ion of Imaging Risk Markers and Presenting and 
nstream Symptom Burden; Including the Domains of 
ical Functioning Treatment Satisfaction, and Quality of Life
ship Between Ischemic Markers and Therapeutic 
ventions Including Drug and Surgical Strategies and 
Ensuing Benefit in Terms of Symptom Resolution
ative Accuracy of Differing Imaging Risk Markers or 
alities and Their Relative Symptom Benefit
 Selectivity
y for Detecting Obstructive CAD
ative Accuracy of Differing Imaging Markers and Their 
ciation With Obstructive CAD
V Imagingial role in collaboration with the scien- pific community for the development of
arge-scale, high-quality, carefully de-
igned clinical trials assessing an overall
echnology. One potential untoward by-
roduct of this emphasis on CER could
e a stifling of technology development
nd/or refocusing of innovation/
iscovery toward non-CV areas where
hese new requirements are not yet man-
ated.
esearch Efforts Aimed at Redesigning
he Quality of Imaging Evidence
he gap in knowledge on the relation-
hip between CV imaging and outcomes
as recently been recognized by the Na-
ional Institutes of Health–National
eart, Lung, and Blood Institute (NIH-
HLBI) in its most recent strategic plan
51). The NHLBI plan called for re-
earch to optimize diagnostic testing and
dentify strategies that improve out-
omes. Historically, the majority of NIH
unding for imaging has been provided
or oncologic imaging through the Na-
ional Cancer Institute. However, the
HLBI plan states that studies are
eeded to “reduce the inappropriate use
f diagnostic tests and treatments”
Challenge 3.1.c), to “evaluate the risks,
enefits, and costs of diagnostic tests and
reatments in representative populations
nd settings” (Challenge 3.2.a), and to
establish evidence-based guidelines for
revention, diagnosis, and treatment and
dentify gaps in knowledge” (Challenge
.3a) (51).
Similarly, the Medicare Evidence De-
elopment & Coverage Advisory Com-
ittee recently called for a higher level of
utcomes evidence for coronary com-
uted tomographic angiography in a
raft NCD (32,33). This draft NCD was
roundbreaking by requiring evidence to
uide health care coverage, and it is
nticipated that similar requirements for
igh levels of evidence will be the main-
tay of CMS policies henceforth. It is
nvisioned that imaging procedures dem-
nstrating a clear societal benefit or im-ized
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322e less affected by Medicare cuts when
ompared with other areas with less
bundant evidence (32,33).
ole of the ACC, ACR, and Imaging
pecialty Societies to Drive
igh-Quality Imaging Research
he ACC and ACR are leaders in driv-
ng health care quality by their guideline
nd appropriateness criteria statements as
ell as by their suite of data registries.
ne such example of a registry that is
riving health care quality is the Cath-
CI Registry run by the ACC National
ardiovascular Data Registry (NCDR).
he CathPCI Registry is a national qual-
ty improvement program that has helped
o shape normative standards for proce-
ural outcomes for patients referred to
nvasive coronary angiography and inter-
entions (52).
Until recently, the ACC and ACR
maging Network (ACRIN) have not
mbarked on similar ventures for CV
maging. It remains feasible that the de-
elopment of a CV imaging registry
ould be integrated with other ACC
egistries and quality improvement pro-
rams; dovetailing with existing data col-
ection tools and workflow. Economies of
cale would be realized for facilities par-
icipating in all of the NCDR registries
o that automated links for post-imaging
utcomes could be ascertained. A recent
roposal has been put forth by the ACC,
CRIN, and the imaging specialty soci-
ties to create a national CV imaging
egistry with the major purpose of accel-
rating high-quality “real-world” CER in
ultimodality CV imaging. This vision
f the future includes a network of inter-
ctive databases that allow for the sys-
ematic and automated capture of clinical
vents and procedures to provide a seam-
ess estimation of “real-world” health
utcomes across procedural and diagnos-
ic care (Fig. 3). vonclusions
harles Dickens once stated: “It was the
est of times, it was the worst of times,”
53) and perhaps this statement aptly
pplies to the current state of CV imag-
ng. Although the diverse array of imag-
ng technologies provide detailed ana-
omic, functional, and molecular
nformation of the heart that is impres-
ive, there remains a large evidence gap
etween the feasibility of their perfor-
ance and the clinical and economic
alue of its use. Given the high rate of
V imaging, there is tremendous pres-
ure to restrain unnecessary or ineffica-
ious growth by refocusing test utilization
oward areas of appropriate use. For CV
magers, establishing pathways of appro-
riate imaging utilization and leading
rograms of accountability in referral pat-
erns will represent marked steps toward
mproving current practice.
However, addressing only utilization is
nsufficient to ensure clinical value with
V imaging. A new, central role for
erformance of CER will be critical to
ngage the imaging scientists to focus
esearch to demonstrate imaging strate-
ies that provide the greatest incremental
CathPCI Registry
Angiography
PCI
ACTION
ACS
AMI
CV Ima
CCTA
Echo
Radionu
Figure 3. Data Linkages to Facilitate Cost and C
CathPCI is a data registry within the American Colle
istry. ACS  acute coronary syndrome; AMI  acut
bypass graft; CCTA  coronary computed tomogra
cardiography; IC3  Improving Continuous Cardiac
NDI  National Center for Health Statistics Nationa
intervention.alue while concurrently not impeding ehe development of new technologies
hat may benefit patients (35). Currently,
he ACC, ACR, and CV imaging spe-
ialty societies, as well as individual re-
earchers are developing applications for
arge-scale outcomes projects in CV im-
ging, including large randomized trials
nd (national and multinational) regis-
ries (47). Several applications have been
roposed to the NHLBI to examine
ER in CV imaging. Should one of
hese be funded, this would represent a
remendous step forward in defining a
et improvement in health outcome fol-
owing CV imaging and, perhaps, issue
n a new era of imaging megatrials. This
atter development is unique to the field
f CV imaging, representing a clear de-
arcation in the quality of clinical re-
earch undertaken. Our hopes for the
uture depend on the development of
arger trials and registries so that we can
ealize the benefit of CV imaging in
mproving the lives of the millions of
atients who undergo testing each year.
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